Typicality: | 0.491 |
Saliency: | 0.413 |
for the treatment of advanced rcc | 12 | purpose |
in 1993 | 4 | temporal |
in the dpp-4 enzyme | 3 | other |
agent → be approved by → the fda | 22 |
agent → be approved by → the food and drug administration | 9 |
agent → be → fda-approved | 6 |
negative | neutral | positive |
0.059 | 0.645 | 0.296 |
Raw frequency | 37 |
Normalized frequency | 0.413 |
Modifier score | 0.700 |
Perplexity | 40.322 |